公开(公告)号：EP1981902A2

公开(公告)日：2008-10-22

申请号：EP07762730.5

申请日：2007-01-26

申请人： Biogen Idec MA Inc.

发明人： LEE, Daniel, H.S. ,  WEN, Dingyi ,  PEPINSKY, R. Blake ,  RELTON, Jane, K. ,  WANG, Xinzhong ,  LUGOVSKOY, Alexey ,  MEIER, Werner ,  GARBER, Ellen, A. ,  SILVIAN, Laura ,  WEINREB, Paul, H.

IPC分类号： C07K7/64

CPC分类号： C07K14/705 ,  A01K67/027 ,  A01K67/0275 ,  A01K2217/058 ,  A01K2227/105 ,  A01K2267/0356 ,  A61K38/179 ,  A61K39/3955 ,  A61K48/00 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2863 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/33 ,  C07K2319/74 ,  C12N15/1136 ,  C12N15/1138 ,  C12N15/8509 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53

摘要： Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.

公开(公告)号：EP1490110B1

公开(公告)日：2012-06-13

申请号：EP03755325.2

申请日：2003-03-13

申请人： Biogen Idec MA Inc. ,  The Regents of The University of California

发明人： VIOLETTE, Shelia, M. ,  WEINREB, Paul, H. ,  SIMON, Kenneth, J. ,  SHEPPARD, Dean ,  LEONE, Diane, R.

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K47/48 ,  A61P17/06 ,  A61P35/00 ,  A61P13/12 ,  A61P11/00 ,  A61P1/16 ,  G01N33/577 ,  C12N15/13 ,  C12N5/20

CPC分类号： C07K16/2839 ,  A61K47/48507 ,  A61K47/48561 ,  A61K47/48623 ,  A61K47/68 ,  A61K47/6835 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6865 ,  A61K51/1027 ,  A61K51/1066 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/57492 ,  G01N33/6893 ,  G01N2333/70546 ,  G01N2800/085 ,  G01N2800/205

摘要： A monoclonal antibody or an antigen binding fragment thereof that (a) specifically binds to ±v²6 but does not bind other av integrins; and (b) does not inhibit the binding of ²6 to latency associated peptide (LAP) with an IC50 value lower than that of 10D5. Said monoclonal antibody, wherein the antibody comprises a) the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 6. 2A1 (ATCC accession number PTA-3896) or b) the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 6.2E5 (ATCC accession number PTA-3897). The disclosure also relates to uses of same and to compositions comprising same.

摘要翻译： （a）特异性结合±v26但不结合其他av整合素的单克隆抗体或其抗原结合片段; 和（b）不抑制结合26与潜伏相关肽（LAP）的结合，IC 50值低于10D5。 所述单克隆抗体，其中所述抗体包含a）与由杂交瘤6 2A1（ATCC登录号PTA-3896）产生的抗体相同的重链和轻链多肽序列或b）与所产生的抗体相同的重链和轻链多肽序列 通过杂交瘤6.2E5（ATCC登录号PTA-3897）。 本公开还涉及其用途和包含其的组合物。

公开(公告)号：EP1920065A2

公开(公告)日：2008-05-14

申请号：EP06774580.2

申请日：2006-07-10

申请人： Biogen Idec MA Inc.

发明人： VIOLETTE, Shelia ,  KOOPMAN, Louise, A. ,  SIMON, Kenneth, J. ,  WEINREB, Paul, H. ,  VAN VLIJMEN, Herman ,  SALDANHA, Jose ,  LUGOVSKOY, Alexey, A.

IPC分类号： C12P21/08 ,  C07K16/00 ,  A61K39/395 ,  G01N33/53 ,  G01N33/574 ,  C12P21/04 ,  C07H21/04

CPC分类号： C07K16/2839 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/77 ,  G01N33/57407 ,  G01N33/57492 ,  G01N33/6893 ,  G01N2333/70546 ,  G01N2800/085 ,  G01N2800/12 ,  G01N2800/20 ,  G01N2800/347 ,  Y10S424/80 ,  Y10S424/801

摘要： The present invention is in the fields of cell biology, immunology and oncology. Specifically, the invention relates to humanized antibodies that recognizes v 6 integrins which comprises a variable region of nonhuman origin and at least -a portion of an immunoglobulin of human origin. The invention also relates to processes for their preparation, to pharmaceutical compositions comprising them and to methods of treating various diseases by administering humanized anti- v 6 antibodies. The invention also relates to the identification of differential expression of the integrin ±v²6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ±v²6.

公开(公告)号：EP1490110A2

公开(公告)日：2004-12-29

申请号：EP03755325.2

申请日：2003-03-13

申请人： Biogen Idec MA Inc. ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： VIOLETTE, Shelia, M. ,  WEINREB, Paul, H. ,  SIMON, Kenneth, J. ,  SHEPPARD, Dean ,  LEONE, Diane, R.

IPC分类号： A61K39/395 ,  C07K16/28 ,  C12N5/12

CPC分类号： C07K16/2839 ,  A61K47/48507 ,  A61K47/48561 ,  A61K47/48623 ,  A61K47/68 ,  A61K47/6835 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6865 ,  A61K51/1027 ,  A61K51/1066 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/57492 ,  G01N33/6893 ,  G01N2333/70546 ,  G01N2800/085 ,  G01N2800/205

摘要： A monoclonal antibody or an antigen binding fragment thereof that (a) specifically binds to ±v²6 but does not bind other av integrins; and (b) does not inhibit the binding of ²6 to latency associated peptide (LAP) with an IC50 value lower than that of 10D5. Said monoclonal antibody, wherein the antibody comprises a) the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 6. 2A1 (ATCC accession number PTA-3896) or b) the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 6.2E5 (ATCC accession number PTA-3897). The disclosure also relates to uses of same and to compositions comprising same.

摘要翻译： 与αvβ6特异性结合的单克隆抗体。 还包括使用这些抗体治疗患有或有风险患有αvβ6介导的疾病或诊断αvβ6介导的疾病的哺乳动物的方法。